DUBLIN, Dec. 18, 2019 /PRNewswire/ -- Perrigo
Company plc (NYSE; TASE: PRGO), today announced that CEO and
President, Murray S. Kessler will
present at the ICR Conference at 9:30 AM EST on Monday, January 13, 2020 at the Grande Lakes
Orlando Resort in Orlando,
Florida.
Mr. Kessler will also present at the 38th Annual J.P.
Morgan Global Healthcare Conference at 4:30 PM EST on Tuesday, January 14, 2020 at the Westin St.
Francis Hotel in San Francisco,
California. Interested parties can access the presentation
webcasts
at http://perrigo.investorroom.com/events-webcasts.
About Perrigo
Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making
lives better by bringing "Quality, Affordable Self-care
Products™" that consumers trust everywhere they are
sold. The Company is a leading provider of over-the-counter
health and wellness solutions that enhance individual well-being by
empowering consumers to proactively prevent or treat conditions
that can be self-managed. Visit Perrigo online
at http://www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"forecast," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "potential" or the negative of those terms or other
comparable terminology. The Company has based these forward-looking
statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: the timing, amount and cost of any
share repurchases; future impairment charges; the success of
management transition; customer acceptance of new products;
competition from other industry participants, some of whom have
greater marketing resources or larger market shares in certain
product categories than the Company does; pricing pressures from
customers and consumers; resolution of uncertain tax positions,
including the Company's appeal of the Notice of Assessment (the
"NoA") issued by the Irish tax authority and the draft and final
Notices of Proposed Assessment ("NOPAs") issued by the U.S.
Internal Revenue Service and the impact that an adverse result in
any such proceedings would have on operating results, cash flows,
and liquidity; potential third-party claims and litigation,
including litigation relating to the Company's restatement of
previously-filed financial information and litigation relating to
uncertain tax positions, including the NoA and the NOPAs; potential
impacts of ongoing or future government investigations and
regulatory initiatives; potential costs and reputational impact of
product recalls or sales halts; the impact of tax reform
legislation and healthcare policy; general economic conditions;
fluctuations in currency exchange rates and interest rates; the
consummation of announced acquisitions or dispositions and the
success of such transactions, and the Company's ability to realize
the desired benefits thereof; and the Company's ability to execute
and achieve the desired benefits of announced cost-reduction
efforts and strategic and other initiatives. Statements
regarding the separation of the RX business, including the expected
benefits, anticipated timing, form of any such separation and
whether the separation ultimately occurs, are all subject to
various risks and uncertainties, including future financial and
operating results, our ability to separate the business, the effect
of existing interdependencies with our manufacturing and shared
service operations, and the tax consequences of the planned
separation to the Company or its shareholders. Furthermore, the
Company may incur additional tax liabilities in respect of 2016 and
prior years or be found to have breached certain provisions of
Irish company law in connection with the Company's restatement of
previously-filed financial statements, which may result in
additional expenses and penalties. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-K for the year ended December 31, 2018, as
well as the Company's subsequent filings with the United States
Securities and Exchange Commission, may cause actual results,
performance or achievements to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/perrigo-to-present-at-upcoming-investor-conferences-300976887.html
SOURCE Perrigo Company plc